Structural optimization of oxaprozin for selective inverse Nurr1 agonism
Sabine Willems(Goethe University Frankfurt), Daniel Merk(Ludwig-Maximilians-Universität München), Romy Busch(Ludwig-Maximilians-Universität München), Felix Nawa(Ludwig-Maximilians-Universität München), Silvia Arifi(Goethe University Frankfurt), Julia Ohrndorf(Goethe University Frankfurt), Julian A. Marschner(Ludwig-Maximilians-Universität München), Beatrice Renelt(Goethe University Frankfurt), Felix F. Lillich(Goethe University Frankfurt), Marco Ballarotto(Ludwig-Maximilians-Universität München), Jörg Pabel(Ludwig-Maximilians-Universität München), Úrsula López-García(Ludwig-Maximilians-Universität München), Lorena A. Rüger(Goethe University Frankfurt), Ewgenij Proschak(Goethe University Frankfurt), Till Kasch(Ludwig-Maximilians-Universität München), Daniel Zaienne(Goethe University Frankfurt)
Cited by 1
Related Papers
Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds
|Journal of Medicinal Chemistry|2018|476
DOGS: Reaction-Driven de novo Design of Bioactive Compounds
|PLoS Computational Biology|2012|264
Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria
|Journal of Medicinal Chemistry|2015|152
The Medicinal Chemistry of Caffeine
|Journal of Medicinal Chemistry|2021|116
<scp>l</scp>-Thyroxin and the Nonclassical Thyroid Hormone TETRAC Are Potent Activators of PPARγ
|Journal of Medicinal Chemistry|2020|49